Mesoblast

Mesoblast Quick Ratio

Quick Ratio (Acid Test) of Mesoblast (MESO) as of Oct 23, 2026.

Quick Ratio

0.00

Last updated:

Quick Ratio (Acid Test) of Mesoblast is 2026 0.00 . Quick Ratio (Acid Test) of Mesoblast was 2025 1.63 . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mesoblast Stock analysis

What does Mesoblast do? Mesoblast Ltd, based in Melbourne, Australia, develops regenerative medicine products using mesenchymal lineage cells. The company focuses on clinical-stage therapies such as Remestemcel-L for inflammatory conditions including graft versus host disease and inflammatory bowel disease, and MPC-300-IV for rheumatoid arthritis. It operates in Australia, the US, Singapore, and Switzerland with 81 employees and is listed on the stock exchange since 2015. Mesoblast is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mesoblast stock

On Eulerpool you can find the complete historical development of Quick Ratio (Acid Test) Mesoblast since 2006 – with annual values, charts, and detailed analysis.

The Quick Ratio measures liquidity by comparing liquid assets to current liabilities, excluding inventory. It is a more conservative measure than the current ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Quick Ratio (Acid Test)'s Mesoblast with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Mesoblast

All Key Metrics — Mesoblast